Quintiles Transitional Holdings (Q) : The total money flow in Quintiles Transitional Holdings (Q) was negative ($2.89 million), which signals selling by the traders on Thursdays session. They trimmed their holdings by selling the stock on downticks to the tune of $14.75 million. In comparison, the inflow of money into the stock on upticks was $11.86 million. The uptick to downtick ratio was 0.8. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $5.12 million. The value of transactions on uptick was $0.68 million. The negative money flow of ($4.44 million) confirms the selling in Quintiles Transitional Holdings (Q) on strength. The uptick to downtick ratio of block trades was 0.13. Quintiles Transitional Holdings (Q) gained $0.42 at $68.73, a gain of 0.61% over the previous days close. However, the stock registered 2.8% in the week.
Quintiles Transitional Holdings (Q) : Average target price received by Quintiles Transitional Holdings (Q) is $74.55 with an expected standard deviation of $6.2. The most aggressive target on the stock is $83, whereas the most downbeat target is $62. 10 financial analysts are currently covering the stock. The stock has recorded a 20-day Moving Average of 6.34% and the 50-Day Moving Average is 4.3%.
Quintiles Transitional Holdings (NYSE:Q): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $68.40 and $68.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $68.99. The buying momentum continued till the end and the stock did not give up its gains. It closed at $68.99, notching a gain of 1.00% for the day. The total traded volume was 1,311,163 . The stock had closed at $68.31 on the previous day.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.